Yahoo · Oct 30, 2026
What Just Happened To Alnylam Stock?
For questions about this article or underlying research, email [email protected].
IO
NASDAQ · IONS
Ionis Pharmaceuticals, Inc.
Healthcare · Biotechnology
$43.52
Down-$0.87 (-1.96%)
Updated Nov 2, 2026, 3:51 AM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 12.57B
- P/E ratio
- -49.61
- Dividend yield
- 0.00%
- 52-week range
- $42.08 – $86.74
- Volume
- 1.52M
- Avg. volume
- 2.43M
Price performance · IONS
IONS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IONS closed at $43.52 after 20 trading sessions, up 0.05% for the selected period.
- Last close
- $43.52
- Period change
- +0.05%
- Period low
- $42.38
- Period high
- $45.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $44.69 | $45.115 | $43.27 | $43.52 | 1.52M |
| Oct 29, 2026 | $45.57 | $45.84 | $44.04 | $44.39 | 1.83M |
| Oct 28, 2026 | $43.16 | $44.95 | $43.05 | $44.90 | 1.72M |
| Oct 27, 2026 | $43.23 | $44.10 | $43.02 | $43.96 | 2.38M |
| Oct 26, 2026 | $43.00 | $43.92 | $42.76 | $43.42 | 3.2M |
| Oct 23, 2026 | $43.80 | $43.80 | $42.58 | $42.93 | 3.02M |
| Oct 22, 2026 | $45.02 | $45.15 | $43.41 | $43.91 | 5.01M |
| Oct 21, 2026 | $45.55 | $45.76 | $44.26 | $44.27 | 2.27M |
| Oct 20, 2026 | $44.45 | $45.48 | $44.01 | $45.40 | 2.49M |
| Oct 19, 2026 | $43.33 | $44.54 | $43.00 | $44.38 | 3.1M |
| Oct 16, 2026 | $44.53 | $44.65 | $42.795 | $42.94 | 1.67M |
| Oct 15, 2026 | $43.58 | $44.71 | $43.4219 | $44.12 | 2.48M |
| Oct 14, 2026 | $42.22 | $43.47 | $42.08 | $42.70 | 2.03M |
| Oct 13, 2026 | $43.55 | $43.575 | $42.36 | $42.38 | 2.98M |
| Oct 12, 2026 | $45.37 | $45.455 | $43.62 | $43.67 | 1.95M |
| Oct 9, 2026 | $43.21 | $45.72 | $43.12 | $45.28 | 4.86M |
| Oct 8, 2026 | $43.76 | $44.19 | $42.79 | $43.30 | 3.35M |
| Oct 7, 2026 | $43.75 | $44.26 | $43.53 | $44.16 | 2.94M |
| Oct 6, 2026 | $44.185 | $44.665 | $43.17 | $44.00 | 2.19M |
| Oct 5, 2026 | $43.75 | $43.96 | $42.63 | $43.50 | 2.87M |
Latest IONS news
The latest Smart Investors Daily articles mentioning IONS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IONS research
Overview
Company profile and research snapshot.
Company profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $83.85
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | BMO Capital | Outperform | — |
| Oct 15, 2026 | UBS | Buy | — |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 22, 2026 | JP Morgan | Overweight | — |
| Sep 15, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 27, 2026
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
